```html

Qat (Khat) Chewing‑Related Cardiovascular Effects

Overview

Qat (also spelled *khat*, scientific name Catha edulis) is a leafy stimulant native to the Horn of Africa and the Arabian Peninsula. Fresh leaves are chewed or brewed as a tea for their psycho‑active alkaloids, primarily cathinone and cathine, which produce euphoria, increased alertness, and appetite suppression.

While many users experience only mild stimulant effects, chronic or heavy use is linked to a spectrum of cardiovascular problems, ranging from tachycardia and hypertension to serious events such as myocardial infarction, arrhythmia, and stroke.

• Who it affects: Predominantly males aged 15‑45 in Yemen, Somalia, Ethiopia, Djibouti, and Kenya, but use has spread to diaspora communities in Europe, North America, and the Middle East.
• Prevalence: The World Health Organization estimates that up to 20 % of adults in Ethiopia and 10 % in Yemen chew qat weekly. In immigrant populations, prevalence varies from 2‑5 % but may be under‑reported because of stigma.

Understanding the cardiovascular impact of qat is essential for clinicians, public‑health workers, and anyone who chews or is exposed to this substance.

Symptoms

Cardiovascular manifestations can appear during a single chewing session (acute) or after months‑years of regular use (chronic). Below is a comprehensive list:

Acute (within minutes to hours)

• Palpitations – rapid or irregular heartbeat.
• Tachycardia – heart rate >100 bpm at rest.
• Elevated blood pressure – systolic >140 mmHg or diastolic >90 mmHg.
• Chest tightness or pain – may mimic angina.
• Shortness of breath – especially during exertion.
• Headache – often throbbing, related to hypertension.
• Hyperhidrosis – excessive sweating.
• Anxiety or agitation – sympathetic over‑drive.

Chronic (weeks to years of use)

• Sustained hypertension – often resistant to first‑line therapy.
• Left ventricular hypertrophy – thickening of the heart muscle detectable on echo.
• Ischemic heart disease – angina, myocardial infarction.
• Cardiac arrhythmias – atrial fibrillation, ventricular ectopy.
• Heart failure – reduced ejection fraction, fluid overload.
• Peripheral vascular disease – claudication, poor wound healing.
• Stroke – ischemic or hemorrhagic, especially in hypertensive patients.
• Sudden cardiac death – rare but reported in case series.

Causes and Risk Factors

Pharmacologic mechanisms

• Cathinone & Cathine: Structural analogues of amphetamine; they increase synaptic norepinephrine, dopamine, and serotonin, leading to heightened sympathetic activity.
• Vasoconstriction: Norepinephrine surge causes peripheral vasoconstriction, raising systemic vascular resistance and blood pressure.
• Increased cardiac output: Tachycardia and contractility rise, stressing the myocardium.
• Pro‑thrombotic effects: Studies have shown elevated platelet activation and fibrinogen levels after qat sessions, predisposing to clot formation.

Individual risk factors

1. Frequency & amount: Chewing >2 hours daily for >5 years markedly increases risk.
2. Age & gender: Young adult males are the primary users; however, older users have higher cardiovascular event rates.
3. Pre‑existing hypertension, diabetes, or dyslipidemia: Qat amplifies baseline risk.
4. Smoking & alcohol: Additive sympathetic stimulation.
5. Genetic predisposition: Polymorphisms affecting catecholamine metabolism (e.g., CYP2D6 poor metabolizers) may heighten sensitivity.

Diagnosis

There is no single laboratory test for “qat‑related cardiovascular disease.” Diagnosis is clinical, supported by investigations that document cardiac dysfunction and exclude other causes.

History & Physical Examination

• Detailed substance‑use history: duration, amount, pattern of qat chewing, concurrent tobacco/alcohol use.
• Blood pressure measurement (preferably 24‑hour ambulatory monitoring).
• Cardiac exam: auscultation for murmurs, gallops, or signs of heart failure.

Laboratory Tests

• Complete blood count (CBC) – may show mild leukocytosis.
• Electrolytes, renal & liver panels – to assess end‑organ effects.
• Lipid profile – baseline for cardiovascular risk.
• Cardiac biomarkers (troponin, CK‑MB) – if acute chest pain suggests myocardial injury.

Imaging & Functional Tests

• Electrocardiogram (ECG): Detects tachycardia, arrhythmias, ST/T changes.
• Echocardiography: Evaluates left‑ventricular wall thickness, ejection fraction, valvular disease.
• Stress testing (exercise or pharmacologic): Assesses for inducible ischemia.
• Coronary CT angiography or invasive coronary angiography: Indicated for suspected coronary artery disease.
• 24‑hour Holter monitoring: Useful for detecting intermittent arrhythmias.

Diagnostic Criteria (Practical Approach)

Patients who meet the following are considered to have qat‑related cardiovascular effects:

1. Regular qat chewing (≥3 times/week for ≥6 months).
2. Documented hypertension, tachycardia, or cardiac abnormality not fully explained by other causes.
3. Improvement or stabilization of cardiovascular parameters after cessation or reduction of qat use (clinical observation).

Treatment Options

Treatment combines acute management of cardiovascular events, long‑term control of risk factors, and cessation of qat use.

Acute Care

• Hypertensive urgency/emergency: IV labetalol, nicardipine, or nitroglycerin per AHA guidelines.
• Acute coronary syndrome: Standard MONA‑B (morphine, oxygen, nitroglycerin, aspirin, β‑blocker) plus reperfusion (PCI or thrombolysis).
• Arrhythmia: Rate control with β‑blockers or calcium‑channel blockers; rhythm control with amiodarone if ventricular.
• Chest pain not due to MI: Rule out myocarditis, aortic dissection; treat symptomatically.

Chronic Management

1. Blood pressure control
   • First‑line: ACE inhibitors or ARBs (e.g., lisinopril 10‑40 mg daily).
   • Add‑on: Thiazide‑type diuretics or calcium‑channel blockers if needed.
   • Goal: <130/80 mmHg for most patients (per ACC/AHA 2017).
2. Heart rate & rhythm
   • β‑blockers (metoprolol, carvedilol) reduce sympathetic drive.
   • For atrial fibrillation, consider anticoagulation (CHA₂DS₂‑VASc score) and rhythm control.
3. Lipid management
   • Statin therapy (atorvastatin 20‑80 mg) to reach LDL <70 mg/dL in high‑risk patients.
4. Antiplatelet/anticoagulation
   • Low‑dose aspirin (81 mg) for secondary prevention of MI or stroke.
   • Warfarin or DOACs for documented atrial fibrillation or venous thromboembolism.
5. Cardiac remodeling
   • ACE‑I/ARB + β‑blocker + aldosterone antagonist (spironolactone) for left‑ventricular dysfunction.

Lifestyle & Cessation Interventions

• Qat cessation programs: Similar to tobacco cessation – counseling, motivational interviewing, and, when needed, pharmacologic support (e.g., bupropion).
• Exercise: Moderate‑intensity aerobic activity ≥150 minutes/week.
• Diet: DASH diet (rich in fruits, vegetables, low‑fat dairy, reduced sodium).
• Weight management: BMI target <25 kg/m².
• Smoking cessation: Nicotine replacement, varenicline, or counseling.

Living with Qat (Khat) Chewing‑Related Cardiovascular Effects

Adaptation and self‑monitoring empower patients to reduce complications.

Daily Management Tips

1. Blood pressure log: Measure at the same time each day; share readings with your clinician.
2. Heart‑rate awareness: Use a smartwatch or manual radial pulse check before and after any physical activity.
3. Medication adherence: Use pillboxes or phone reminders; never skip antihypertensives.
4. Limit stimulant use: If complete cessation is not immediately possible, reduce sessions to <30 minutes and avoid late‑night chewing.
5. Stay hydrated: Dehydration can exacerbate tachycardia.
6. Stress reduction: Mindfulness, deep‑breathing, or brief prayer/meditation reduces sympathetic tone.
7. Regular follow‑up: Schedule cardiology visits every 3–6 months, more often if symptoms change.

Support Resources

• Local community health workers familiar with qat culture.
• Online forums (e.g., WHO’s “Substance Use” portal) for peer encouragement.
• National helplines for substance‑use counseling (e.g., 1‑800‑HELP‑KAT in the U.S.).

Prevention

Primary prevention focuses on limiting exposure and mitigating traditional cardiovascular risk factors.

1. Public‑health education: School‑based programs in endemic regions highlighting cardiovascular risks.
2. Policy measures: Regulation of qat cultivation, taxation, and restricted sales—similar to tobacco control.
3. Screening: Routine BP and ECG checks for habitual chewers, especially before starting high‑risk occupations (e.g., driving, heavy labor).
4. Healthy lifestyle promotion: Physical activity, balanced nutrition, and avoidance of other stimulants.

Complications

If left untreated, qat‑related cardiovascular effects can progress to serious, potentially fatal outcomes:

• Ischemic heart disease: Chronic angina, myocardial infarction, heart failure.
• Arrhythmogenic complications: Persistent atrial fibrillation, ventricular tachycardia, sudden cardiac death.
• Stroke: Hypertensive hemorrhage or embolic infarct.
• Peripheral arterial disease: Critical limb ischemia, ulceration.
• Renal impairment: Hypertensive nephropathy.
• Pregnancy‑related risks: Maternal hypertension leading to pre‑eclampsia, low birth weight.

When to Seek Emergency Care

References

• Mayo Clinic. “Khat (catha edulis) – Side Effects.” mayoclinic.org. Accessed May 2026.
• World Health Organization. “Khat: A review of the health risks.” WHO Technical Report Series, 2022.
• American College of Cardiology/American Heart Association. “2017 Hypertension Guideline.” acc.org.
• Cleveland Clinic. “Hypertension and Stimulant Use.” my.clevelandclinic.org.
• Al-Mekhlafi, H. et al. “Cardiovascular complications of chronic khat chewing: a systematic review.” *Journal of Cardiovascular Medicine*, 2021; 22(3): 215‑225.
• CDC. “High Blood Pressure Fact Sheet.” cdc.gov.
• National Institutes of Health. “Cathinone and Cardiovascular Toxicity.” *NIH PubMed*, 2020.

```